Study setupModel establishment and tissue characterization; drug or immune conditions configured for follow-on studies
AssaysBright-field, H&E, hepatic/epithelial and endothelial markers; efficacy or immune endpoints configured for follow-on work
STUDY EVIDENCE
Culture morphology and tissue identity in liver-cancer PDO 2.0
Culture morphology, histology and immunohistochemistry establish model context and guide endpoint selection for follow-on efficacy and mechanism studies.
Liver-cancer PDO 2.0 culture, histology and identity profiling
PDO culture morphology is evaluated with source-tissue/PDO H&E and endothelial- and hepatocyte-related IHC to connect culture, tissue structure and lineage context.
Guides model and endpoint selection for efficacy and mechanism studies
Conventional HCC PDO culture and whole-mount immunofluorescence
Bright-field and whole-mount immunofluorescence in a conventional HCC PDO document morphology and cell state, adding a complementary conventional-PDO view to liver-cancer study design.
Adds conventional-PDO morphology and cell-state context
INTERPRETATION
Select the study direction around the liver-tumor context
How the results are used
Defines efficacy or mechanism study directions for the profiled liver-tumor samples.
Study application
Interpret results in the context of sample pathology, tissue source, culture morphology and markers, then use them to design efficacy and mechanism studies.
Follow-on study
Build pathology- and target-informed dose, time-course and additional-sample studies.
Related models and services
Choose the right models and services for the next study
